Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 plus Atezolizumab in Advanced Oesophagogastric Cancer
NCT04166721Phase 2Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2020
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirexatamab in gastroesophageal junction cancer, sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Recommended Phase 2 Dose at 28 days and Objective Response Rate at 24 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
sirexatamab
03
Conditions
gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04166721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166721.